✦ LIBER ✦

Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis

✍ Scribed by Pardanani, A; Laborde, R R; Lasho, T L; Finke, C; Begna, K; Al-Kali, A; Hogan, W J; Litzow, M R; Leontovich, A; Kowalski, M; Tefferi, A

Book ID: 120374575
Publisher: Nature Publishing Group
Year: 2013
Tongue: English
Weight: 510 KB
Volume: 27
Category: Article
ISSN: 0887-6924
DOI: 10.1038/leu.2013.71

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety and Efficacy of INCB018424, a JAK

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

✍ Verstovsek, Srdan; Kantarjian, Hagop; Mesa, Ruben A.; Pardanani, Animesh D.; Cor 📂 Article 📅 2010 🏛 Massachusetts Medical Society 🌐 English ⚖ 542 KB

Balancing efficacy and safety of JAK inh

Balancing efficacy and safety of JAK inhibitors in myelofibrosis

✍ Passamonti, Francesco 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 183 KB

Ruxolitinib, an oral JAK1 and JAK2 inhib

Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis

✍ Vaddi, Kris; Sarlis, Nicholas J; Gupta, Vikas 📂 Article 📅 2012 🏛 Informa plc 🌐 English ⚖ 545 KB

CYT387, a selective JAK1/JAK2 inhibitor:

CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients

✍ Pardanani, A; Lasho, T; Smith, G; Burns, C J; Fantino, E; Tefferi, A 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 136 KB

Allogeneic hematopoietic cell transplant

Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib

✍ Jaekel, N; Behre, G; Behning, A; Wickenhauser, C; Lange, T; Niederwieser, D; Al- 📂 Article 📅 2013 🏛 Nature Publishing Group 🌐 English ⚖ 313 KB

Efficacy and safety of topical INCB01842

Efficacy and safety of topical INCB018424, a selective Janus kinase 1 & 2 (JAK1&2) inhibitor in psoriasis

📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 62 KB